Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2023-04-25 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 98% confidence The document is an announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). While the document mentions an attachment, the core content is a notification of director/managerial dealing, which falls under the 'Director's Dealing' category. The document length is short, but it explicitly identifies the nature of the transaction as a PDMR disclosure, which is a specific regulatory requirement.
2023-04-25 English
Director's Dealing 2023
Director's Dealing Classification · 100% confidence The document text is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details specific transactions (Sale of Shares) conducted by individuals identified as members of the Board of Directors (persons discharging managerial responsibilities) of Zealand Pharma A/S. This content directly corresponds to the definition of Director's Dealing (insider trades) as per the provided schema. The corresponding code is DIRS.
2023-04-19 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document contains multiple standardized templates for the 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMRs). These templates explicitly list board members and employees of Zealand Pharma A/S, their positions, and details of their transactions (specifically the allocation of Restricted Stock Units). This is a classic 'Director's Dealing' or 'Insider Trading' disclosure, which falls under the DIRS category.
2023-04-19 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is an announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). While it mentions that details are in an attached file, the primary purpose of this specific text is to report insider dealings as required by regulatory disclosure rules. Therefore, it falls under the 'Director's Dealing' category.
2023-04-19 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 98% confidence The document is a company announcement titled "Zealand Pharma completes registration of capital increase." It explicitly details the completion and registration of a capital increase involving the issuance of 6,578,948 new shares, which directly impacts the company's share capital structure. This action falls under financing activities and capital structure changes. Based on the provided definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA).
2023-04-04 English
Approval of prospectus for ZEALAND PHARMA A/S; Shares
Share Issue/Capital Change Classification · 95% confidence The document is a formal 'Prospectus' for Zealand Pharma A/S, specifically prepared for the admission to trading and official listing of new shares on Nasdaq Copenhagen. It contains detailed sections on risk factors, business description, financial information, and board composition, as required by the Prospectus Regulation. Since it is a capital-related document regarding the issuance and listing of shares, it falls under the 'Capital/Financing Update' category.
2023-04-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.